Applied Genetic Technologies Corp (AGTC) Shares Sold by Fmr LLC
Fmr LLC lowered its position in Applied Genetic Technologies Corp (NASDAQ:AGTC) by 80.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 35,911 shares of the biotechnology company’s stock after selling 146,198 shares during the quarter. Fmr LLC’s holdings in Applied Genetic Technologies were worth $133,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in Applied Genetic Technologies by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 731,898 shares of the biotechnology company’s stock worth $2,708,000 after purchasing an additional 99,358 shares in the last quarter. Acadian Asset Management LLC bought a new position in Applied Genetic Technologies in the second quarter worth approximately $2,538,000. Point72 Asset Management L.P. bought a new position in Applied Genetic Technologies in the first quarter worth approximately $693,000. Ancora Advisors LLC grew its stake in Applied Genetic Technologies by 270.8% in the first quarter. Ancora Advisors LLC now owns 74,154 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 54,154 shares in the last quarter. Finally, Marquette Asset Management LLC bought a new position in Applied Genetic Technologies in the second quarter worth approximately $129,000. 48.47% of the stock is currently owned by institutional investors.
Applied Genetic Technologies stock opened at $6.48 on Friday. The firm has a market cap of $132.34 million, a price-to-earnings ratio of -5.49 and a beta of 2.04. Applied Genetic Technologies Corp has a twelve month low of $3.25 and a twelve month high of $7.50.
Several brokerages recently issued reports on AGTC. Zacks Investment Research cut Applied Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. HC Wainwright set a $8.00 target price on Applied Genetic Technologies and gave the stock a “buy” rating in a report on Monday, July 23rd. Chardan Capital lowered Applied Genetic Technologies from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $10.00 to $5.00 in a report on Tuesday, September 11th. Finally, Wells Fargo & Co upgraded Applied Genetic Technologies from a “market perform” rating to an “outperform” rating and lowered their target price for the stock from $20.00 to $6.00 in a report on Monday, September 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $6.88.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.
Recommended Story: Hedge Funds
Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corp (NASDAQ:AGTC).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.